Association between Insulin Resistance and Recurrent Stroke in Patients with Non-disabling Ischemic Cerebrovascular Events

doi:10.3969/j.issn.1673-5765.2019.10.008

Abstract

Abstract:

Objective To explore the effect of different insulin resistance state on the prognosis of patients with non-disabling ischemic cerebrovascular events (NICE). Methods The homeostasis model HOMA-IR index was used to evaluate insulin resistance. According to different insulin resistance status, patients were divided into four groups by quartile method. The primary endpoint was 90-day new-onset stroke (including ischemic and hemorrhagic stroke). Multivariate Cox regression model was used to assess the relationship between different insulin resistance status and recurrent stroke. The interaction between different antiplatelet therapeutic regimen and different insulin resistance status on recurrent stroke was also analyzed. Results A total of 2325 NICE patients were enrolled in this study. According to different insulin resistance status, all patients were divided into 4 groups: Q1 (HOMA-IR index <1.35), Q2 (1.35≤ HOMA-IR index <2.17), Q3 (2.17≤ HOMA-IR index <3.39) and Q4 (HOMA-IR index ≥3.39) group. The number of patients in Q1, Q2, Q3 and Q4 group were 585, 575, 585 and 580,respectively. Within 90 days of follow-up, recurrent stroke occurred in 167 patients, including 68 ones in clopidogrel combined with aspirin group and 99 ones in aspirin group. The risk of recurrent stroke in Q2 group (9.2% vs 6.3%; adjusted HR 1.56, 95%CI 1.01-2.41; P =0.04), Q3 group (5.6% vs 6.3%; adjusted HR 1.04, 95%CI 0.64-1.69; P =0.89) and Q4 group (7.6% vs 6.3%; adjusted HR 1.35, 95%CI 0.85-2.15; P =0.21) all did not increase significantly compared with that in Q1 group. Conclusions Insulin resistance is not associated with an increased risk of recurrent stroke in patients with mild stroke and TIA.

Key words: Non-disabling ischemic cerebrovascular events; Insulin resistance; Prognosis;Recurrent stroke

摘要：

目的探讨不同胰岛素抵抗状态对无糖尿病史的非致残性缺血性脑血管病（non-disabling ischemic cerebrovascular events，NICE）患者卒中复发风险的影响。方法使用稳态模型胰岛素抵抗（homeostasis model assessment of insulin resistance，HOMA-I R）指数对胰岛素抵抗进行评估。根据不同胰岛素抵抗状态，使用四分位法将无糖尿病史的NICE患者分为4 组。该研究的主要研究终点为90 d新发卒中（包括缺血性和出血性卒中）。利用多元Cox回归模型校正潜在协变量，评估不同胰岛素抵抗状态与卒中复发风险之间的关系，同时对不同抗血小板聚集治疗、不同胰岛素抵抗状态与卒中复发之间的交互作用进行统计分析。结果本研究共纳入2325例NICE患者。根据患者不同胰岛素抵抗状态分组，4组界值分别为Q1 （HOMA-IR指数﹤1.35）、Q2（1.35≤HOMA-IR指数﹤2.17）、Q3（2.17≤HOMA-IR指数﹤3.39）及Q4（HOMAIR 指数≥3.39），4组患者人数分别为585例、575例、585例及580例。90 d随访时，共出现167例卒中复发，其中氯吡格雷联合阿司匹林组为68例，阿司匹林组为99例。与Q1组（6.3%）比较，Q2组（9.2%，校正HR 1.56，95%CI 1.01～2.41，P =0.04）、Q3组（5.6%，校正HR 1.04，95%CI 0.64～1.69，P =0.89）和 Q4组（7.6%，校正HR 1.35，95%CI 0.85～2.15，P =0.21）患者卒中复发风险均未明显上升。结论本研究未在NICE患者中发现胰岛素抵抗与卒中复发风险升高相关。

关键词: 非致残性缺血性脑血管病; 胰岛素抵抗; 预后; 卒中复发

CHEN Wei-Qi, ZHANG Guo-Jun, PAN Yue-Song, LIN Jin-Xi, LIANG Xian-Hong, LI Shang-Zhi, WANG Yi-Long, JING Jing, ZHAO Xing-Quan, LIU Li-Ping, WANG Yong-Jun. Association between Insulin Resistance and Recurrent Stroke in Patients with Non-disabling Ischemic Cerebrovascular Events[J]. Chinese Journal of Stroke, 2019, 14(10): 1004-1010.

陈玮琪, 张国军, 潘岳松, 林金嬉, 梁宪红, 李上智, 王伊龙, 荆京, 赵性泉, 刘丽萍, 王拥军. 胰岛素抵抗与非致残性缺血性脑血管病患者卒中复发之间的关系[J]. 中国卒中杂志, 2019, 14(10): 1004-1010.

References

[1] KIM A S，JOHNSTON S C. Temporal and

geographic trends in the global stroke epidemic[J].

Stroke，2013，44（6 Suppl 1）：S123-S125.

[2] KIM A S，JOHNSTON S C. Global variation in

the relative burden of stroke and ischemic heart

disease[J]. Circulation，2011，124（3）：314-323.

[3] FEIGIN V L，MENSAH G A，NORRVING B，et

al. Atlas of the global burden of stroke（1990-2013）：

the GBD 2013 study[J]. Neuroepidemiology，2015，

45（3）：230-236.

[4] COULL A J，LOVETT J K，ROTHWELL P M，et

al. Population based study of early risk of stroke

after transient ischaemic attack or minor stroke：

implications for public education and organisation of

services[J]. BMJ，2004，328（7435）：326.

[5] JOHNSTON S C，GRESS D R，BROWNER W S. et

al. Short-term prognosis after emergency department

diagnosis of tia[J]. JAMA，2000，284（22）：2901-

2906.

[6] AMARENCO P，LAVALLÉE P C，LABREUCHE J，

et al. One-year risk of stroke after transient ischemic

attack or minor stroke[J]. NEJM，2016，374（16）：

1533-1542.

[7] SATO S，UEHARA T，OHARA T，et al. Factors

associated with unfavorable outcome in minor

ischemic stroke[J]. Neurology，2014，83（2）：174-

181.

[8] KERNAN W N，INZUCCHI S E，VISCOLI C M，et

al. Impaired insulin sensitivity among nondiabetic

patients with a recent tia or ischemic stroke[J].

Neurology，2003，60（9）：1447-1451.

[9] KERNAN W N，INZUCCHI S E，VISCOLI C

M，et al. Insulin resistance and risk for stroke[J].

Neurology，2002，59（6）：809-815.

[10] MATHER K J，STEINBERG H O，BARON A D.

Insulin resistance in the vasculature[J]. J Clin Invest，

2013，123（3）：1003-1004.

[11] SEMENKOVICH C F. Insulin resistance and

atherosclerosis[J]. J Clin Invest，2006，116（7）：

1813-1822.

[12] KERNAN W N，VISCOLI C M，FURIE K L，et al. Pioglitazone after ischemic stroke or transient

ischemic attack[J]. N Engl J Med，2016，374（14）：

1321-1331.

[13] MATTHEWS D R，HOSKER J P，RUDENSKI A

S，et al. Homeostasis model assessment：insulin

resistance and beta-cell function from fasting

plasma glucose and insulin concentrations in man[J].

Diabetologia，1985，28（7）：412-419.

[14] BALKAU B，CHARLES M A. Comment on the

provisional report from the WHO consultation.

European Group for the Study of Insulin Resistance

（EGIR）[J]. Diabet Med，1999，16（5）：442-443.

[15] ASCASO J F，PARDO S，REAL J T，et al.

Diagnosing insulin resistance by simple quantitative

methods in subjects with normal glucose

metabolism[J]. Diabetes Care，2003，26（12）：3320-

3325.

[16] RUNDEK T，GARDENER H，XU Q，et al. Insulin

resistance and risk of ischemic stroke among

nondiabetic individuals from the northern manhattan

study[J]. Arch Neurol，2010，67（10）：1195-1200.

[17] THACKER E L，PSATY B M，MCKNIGHT B，

et al. Fasting and post-glucose load measures of

insulin resistance and risk of ischemic stroke in older

adults[J]. Stroke，2011，42（12）：3347-3351.

[18] HISHINUMA A，MAJIMA M，KURABAYASHI H.

Is insulin resistance related to recurrence of stroke

or incident of ischemic heart disease in patients

with stroke? A preliminary report[J]. J Stroke

Cerebrovasc Dis，2009，18（4）：294-297.

[19] BRAVATA D M，WELLS C K，KERNAN W N，et

al. Association between impaired insulin sensitivity

and stroke[J]. Neuroepidemiology，2005，25（2）：

69-74.

[20] WANG Y J, WANG Y L, ZHAO X, et al. Clopidogrel

with aspirin in acute minor stroke or transient

ischemic attack[J]. N Engl J Med，2013，369（1）：

11-19.

[21] 陈小转，李庆利. 胰岛素抵抗与缺血性脑卒中的相关

性[J]. 中医药临床杂志，2012，24（3）：250-252.

[22] 刘玮，赵瑞敏，陈晋文，等. 胰岛素抵抗与缺血性

脑卒中的相关性研究[J]. 卒中与神经疾病，2010，17

（6）：362-364.

[23] BONORA E，KIECHL S，WILLEIT J，et al.

Insulin resistance as estimated by homeostasis

model assessment predicts incident symptomatic

cardiovascular disease in caucasian subjects from the

general population：the Bruneck study[J]. Diabetes

Care，2007，30（2）：318-324.

[24] HUANG Y，CAI X，MAI W，et al. Association

between prediabetes and risk of cardiovascular

disease and all cause mortality：systematic review

and meta-analysis[J/OL]. BMJ，2016，355：i5953.

https：//doi.org/10.1136/bmj.i5953.

[25] HOWARD G，WAGENKNECHT L E，KERNAN

W N，et al. Racial differences in the association of

insulin resistance with stroke risk：the REasons

for Geographic And Racial Differences in Stroke

（REGARDS）study[J]. Stroke，2014，45（8）：2257-

2262.

[26] KANEDA Y，ISHIKAWA S，SADAKANE A，et

al. Insulin resistance and risk of cerebral infarction

in a Japanese general population：the Jichi Medical

School Cohort Study[J]. Asia Pac J Public Health，

2015，27（2）：NP572-579.